Breakthrough Device That Improves Gait In People With MS Authorized By FDA

 
• By Shawn M. Schmitt

The US FDA has granted de novo authorization to the Portable Neuromodulation Stimulator from Helius Medical Technologies. The PoNS device, previously given breakthrough status by the agency in May 2020, can improve the gait of patients with multiple sclerosis.

The Portable Neuromodulation Stimulator (PoNS) device.
The Portable Neuromodulation Stimulator (PoNS) device • Source: Helius Medical Technologies Inc.

The US Food and Drug Administration has granted de novo authorization for a device that can improve gait in people with multiple sclerosis (MS).

The FDA said on 26 March that it has authorized the Portable Neuromodulation Stimulator (PoNS), made by Helius Medical...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Policy & Regulation

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By Elizabeth Orr

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.

MHRA’s Tallon Hails PMS Regulation As Start Of UK Device Framework Transformation

 
• By Ashley Yeo

16 June marked the first major new regulatory instrument in the UK’s post-Brexit transition to a standalone device regulatory system for Great Britain.

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By Elizabeth Orr

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.